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Abstract Sarcopenia is a complex syndrome characterized
by progressive and generalized loss of skeletal muscle
mass and strength. Malignancy is a major determinant of
sarcopenia, and gastric cancer (GC) is among the most
common causes of this phenomenon. As sarcopenia is a
well-recognized poor prognostic feature in GC and has
been associated with worse tolerance of surgical and
medical treatments, members of the multidisciplinary team
should be aware of the clinical relevance, pathogenic
mechanisms, and potential treatments for this syndrome.
The importance of sarcopenia is often underestimated in
everyday practice and clinical trials, particularly among
elderly or fragile patients. As treatment options are
improving in all disease stages, deeper knowledge and
greater attention to the metabolic balance in GC patients
could further increase the benefit of novel therapeutic
strategies and dramatically impact on quality of life. In this
review, we describe the role of sarcopenia in different
phases of GC progression. Our aim is to provide
oncologists and surgeons dealing with GC patients with a
useful tool for comprehensive assessment and timely
management of this potentially life-threatening condition.
Keywords Sarcopenia  Gastric cancer  Nutritional
assessment  Malnutrition  Weight loss
Introduction
Gastric cancer (GC) is the fifth most common cancer and
the third leading cause of cancer death worldwide [1].
Despite some improvements, GC prognosis is still poor,
with surgical resection remaining the most effective ther-
apy for potentially curable GC. However, as the population
ages and an increasing number of older patients requires
complex gastrointestinal surgical procedures, gastrectomy
is associated with higher complication and postoperative
mortality rates [2], while the underpinning cancer may
promote muscle atrophy, particularly in the elderly.
The definition of sarcopenia encompasses decreased
muscle strength, fatigue and metabolic disorders initiated
by a reduction in skeletal muscle mass, which is charac-
terized by atrophy and reduction of muscle tissue quality.
In the sarcopenic processes, muscle fibers are replaced by
fibrotic tissue, resulting in increased frailty and function
deterioration, with neuromuscular junction degeneration
and alterations in oxidative stress and muscle metabolism
[3].
The pathogenesis of sarcopenia is complex and multi-
factorial. It may include disuse, altered endocrine function,
chronic diseases, inflammation, insulin resistance, and
nutritional deficiencies [4]. In conditions such as malig-
nancy, rheumatoid arthritis, and aging, the loss of muscle
mass may be associated with preserved or even increased
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body fat content. Consequently, there could be marked
weakness despite normal weight; this condition is called
‘‘sarcopenic obesity’’ [5] (Fig. 1).
Obesity and sarcopenia may potentiate each other and
act synergistically causing physical impairment and meta-
bolic disorders, and worsening prognosis. Moreover,
increasing visceral fat content may promote the secretion
of proinflammatory cytokines, leading to a catabolic effect
on muscles, as well as insulin resistance [6]. Several
studies have recently reported that inflammation may be
directly associated with sarcopenia [7].
Although sarcopeniamay be a component of cachexia, the
two conditions differ. ‘‘Cachexia’’ is a term originating from
the Greek kakos and hexis, meaning ‘‘bad condition’’ and
defining those patients who lose more than 5% of body
weight within 12 months or less [8]. Among GC patients,
about 85% develop cachexia [9]. The cachectic state is a life-
threatening syndrome observed in many pathological con-
ditions other than cancer, such as chronic obstructive pul-
monary disease, sepsis, and chronic heart failure [10, 11]. It
encompasses skeletal muscle and adipose tissue loss, and it is
frequently associated with muscle atrophy and a deregulated
metabolic state with increased basal energy expenditure and
resistance to conventional nutritional support [12]. In con-
trast, the nonmuscle protein compartment is relatively
preserved, thus distinguishing cachexia from starvation [13].
Additionally, cachexia–associated cytokines are able to
cross the blood–brain barrier and modify the activity of
hunger regulatory systems. As a result, cancer patients with
cachexia often develop anorexia, the incidence rate of which
ranges from 15% to 40% [14].
Cachexia contributes substantially to morbidity and
mortality in cancer patients, accounting for more than 20%
of cancer deaths [12, 15] [15]. Chronic inflammation with
elevated levels of circulating inflammatory cytokines is
consistently observed in cachectic cancer patients. Tumor
cells produce both proinflammatory and procachectic fac-
tors, which stimulate a host inflammatory response. Pro-
cachectic factors include proteolysis-inducing and lipid-
mobilizing factors [12, 16]. Inflammatory cytokines may
trigger muscle wasting by increasing the level of nuclear
factor jB or by causing the release of other cytokines.
Tumor necrosis factor a and proteolysis-inducing factor
cause skeletal muscle atrophy in cachectic patients as they
both increase protein degradation through the ubiquitin–
proteasome pathway and reduce protein synthesis through
phosphorylation of eukaryotic initiation factor 2a [17].
Other factors overexpressed in cancer cachexia include
angiotensin II, myostatin, and activin A, whose upregula-
tion inhibits muscle growth [9].
Fig. 1 Principal molecular pathways underpinning sarcopenia develop-
ment.ACTH adrenocorticotropic hormone,ActRIIB ,BAT brown adipose
tissue, GR glucocorticoid receptor, IGF-1R insulin-like growth factor 1
receptor, IL interleukin, IKK IjB kinase, mTOR mammalian target of
rapamycin,NF-jBnuclear factorjB,PI3Kphosphatidylinositol3-kinase,
PIFR , PKR , TNF tumor necrosis factor, TNFR tumor necrosis factor
receptor
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Additionally, a number of neuroendocrine factors may
also be deregulated, leading to insulin resistance, reduced
anabolic activity, and elevated cortisol levels, and are
potential targets for therapeutic interventions [16].
Here we review the role of sarcopenia onset in the
management of GC to better understand its prognostic
impact and potential improvements in all the settings of GC
treatment.
Impact of sarcopenia on the surgical management
of GC
Despite the development of new therapeutic options, gas-
tric surgery with adequate lymph node dissection remains
the mainstay of treatment for patients with resectable GC
[18, 19]. However, gastrectomy is associated with signifi-
cant risks of postoperative complications, morbidity, and
death [20]. Moreover, GC mainly affects elderly people,
and the association between advanced age and less favor-
able postoperative outcomes has been widely demonstrated
[21, 22]. In addition, since the incidence of malnutrition in
GC patients ranges from 60% to 85% [23, 24] and repre-
sents a well-known prognostic factor and an important
determinant of frailty, a preoperative nutritional assessment
is a key step to overcome possible complications.
Sarcopenia is an independent predictor of postsurgical out-
comes in many types of gastrointestinal cancers [25–27],
including GC [19]. The American College of Surgeons high-
lighted the importance of incorporating both sarcopenia and
frailty in the preoperative risk assessment of older GC patients
[28]. Tegels et al. [29] described a strong correlation between
these two factors and postoperative mortality after gastric sur-
gery. Additionally, preoperative hypolbuminemia and poor
nutritional status, low hemoglobin levels, and the presence of
comorbidities such as diabeteswere associatedwith sarcopenia,
frailty, and consequently poor short-term and long-term out-
comes [22, 30, 31]. The reasons why sarcopenia independently
predicts major complications in GC patients undergoing gas-
trectomy has been hypothesized [2]. Firstly, the association
between sarcopenia and indexes of poor nutritional status (low
BMI, low albumin levels) could increase the postsurgical
complication rate [32]. Secondly, the loss of muscle mass and
functionwould decrease physical ability and autonomy in daily
activities, hindering the normal postoperative recovery [33].
Thirdly, sarcopenia correlates with a higher postsurgical
infection rate, longer hospitalization, more frequent need for
mechanical ventilation, and a greater number of hospital read-
missions and rehabilitation programs [34], with increased
health care costs [35].
With respect to long-term postsurgical outcome, sar-
copenia was independently associated with overall survival
and disease-free survival. Compared with indolent tumors,
cancers withmore aggressive behavior tended to have higher
metabolic activity, leading to systemic inflammation and
sarcopenia [36]. Some authors have also suggested the
potential role of myokines, reporting an increased rate of GC
relapse due to the depletion of muscle mass and the conse-
quent reduction of myokine secretion; these molecules seem
to inhibit the growth of cancer cells [37]. Moreover, sar-
copenia was associated with toxicity in GC patients under-
going neoadjuvant [38] or adjuvant [2] treatment, leading to
early discontinuation of chemotherapy, reduced efficacy of
anticancer drugs, and poor prognosis. Finally, the previously
mentioned high postoperative complication rate contributes
to worse long-term prognosis [19, 39].
The effect on overall survival and disease-free survival
seems to be more evident in stage II and stage III GC patients;
Zhuang et al. [2] found that sarcopenic patients had a signifi-
cantly shorter overall survival (hazard ratio 1.653, p\0.001)
and a significantly lower disease-free survival rate (hazard
ratio 1.620, p\ 0.001) than nonsarcopenic patients when
adjustmentwasmade for disease stage. This is probably due to
the most likely development of sarcopenia in patients with
more aggressive tumors.
Notably, different stages of sarcopenia as defined by the
European Working Group on Sarcopenia [5] seem to impact
differently on postoperative outcome. Huang et al. [40] high-
lighted the importance of sarcopenia classification in stratifying
the risk of postoperative complications. They reported worse
postgastrectomy outcomes with advancing sarcopenia stages;
furthermore, the three-grade classification (presarcopenia, sar-
copenia, and severe sarcopenia) seemed to independently pre-
dict postoperative complications. To distinguish the different
grades of sarcopenia, it is crucial to evaluate not only skeletal
muscle mass but also muscle function and physical ability.
Sarcopenic obesity is another emerging point to consider
in the preoperative evaluation of GC patients. A sixfold
increased risk of postoperative complications in obese
sarcopenic patients undergoing gastrectomy has been
reported [41, 42], as well as a higher risk of infection after
laparoscopic gastrectomy.
Finally, the early integration of nutritional screening
[23] and prehabilitation programs such as preoperative
exercises to increase muscle mass combined with person-
alized nutritional support [40] was demonstrated to be
crucial in reversing sarcopenia and improving short-term
and long-term gastrectomy-related outcomes.
Nutrition in GC patients: risk assessments
and nutritional treatment
Historically, malnutrition has been recognized as an
important prognostic factor in cancer patients, with a
shorter survival reported in patients who experienced
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weight loss before chemotherapy [43]. In GC patients,
malnutrition may arise from the obstructive effect of the
tumor [12] and may be increased by treatment-related side
effects.
Beyond anthropometric measures, biochemical and
functional indicators such as C-reactive protein and albumin
blood concentration are helpful to identify malnutrition
through grading scales for a risk assessment score [44]. In
recent years, several tools for the evaluation of nutritional
status have been developed, such as the Mini Nutritional
Assessment (MNA) [45] and the Subjective Global Assess-
ment (SGA) [46]. The first one was developed to provide a
quick nutritional assessment of elderly patients through the
evaluation of their height, weight, weight loss, lifestyle,
dietary intake, mobility, and comorbidities. After its vali-
dation in clinical practice, it became a useful tool also in
oncology. The SGA was compared with six other objective
techniques (serum albumin level, transferrin level, anthro-
pometry, ideal weight, body fat percentage, total lymphocyte
count, and creatinine–height index) in surgical patients, and
was found to be themost sensitive and specific tool to predict
nutrition-related complications.
Later, Bauer et al. [47] investigated the potential role of
the Patient-Generated SGA (PG-SGA), showing higher
accuracy in identifying malnourished cancer patients than
the SGA, with a sensitivity of 98% and a specificity of
82%. The PG-SGA provides an overall global rating divi-
ded into three categories: well nourished, moderately
malnourished or suspected of being malnourished, and
severely malnourished. Notably, the Oncology Nutrition
Dietetic Practice Group of the American Dietetic Associ-
ation adopted this scale as the standard tool for nutrition
assessment for cancer patients.
The nutritional risk index (NRI) is another useful tool to
stratify nutritional risk [48] in GC patients undergoing
surgery. The NRI is a simple equation that uses serum
albumin concentration and recent weight loss to identify
malnourished patients. A low NRI was associated with a
higher risk of surgical wound complications. Similarly, the
prognostic nutritional index is calculated with the serum
albumin concentration and lymphocytes count in peripheral
blood [49]. Another nutritional screening tool widely used
also in GC surgical patients is the Nutritional Risk
Screening 2002 [50, 51], which is endorsed by the Euro-
pean Society for Clinical Nutrition and Metabolism and
evaluates nutritional risk, taking into account both the
nutritional status and the severity of the disease.
Considering the limitations in the accurate measurement
of nutritional status and different available tools, a com-
bination of objective variables (anthropometric and labo-
ratory measurements) and a subjective scoring system is
necessary to optimally treat potentially resectable GC
patients.
As the preoperative nutritional condition of patients
undergoing surgery can directly influence postoperative
prognosis, overall survival, and disease-free survival, a
timely and appropriate preoperative nutritional support
may improve postsurgical outcomes of GC patients [52].
Even though parenteral nutrition or preoperative enteral
nutrition was associated with a better prognosis and fewer
postoperative complications [53], the addition of immune-
stimulating nutrients did not correlate with lower mortality
rates in surgically resected GC patients (risk ratio 1.1, 95%
confidence interval 0.93–1.31) according to a systematic
review of 2419 patients from 22 randomized clinical trials
[54].
Similarly, postoperative nutritional support plays a
crucial role in the management of the catabolic effect of
gastrointestinal surgery. Early enteral feeding soon fol-
lowed by solid soft food on the third postoperative day is
feasible, safe, and associated with shorter hospitalization
[55–57].
Moreover, since up to 50% of resected GC patients
develop anemia [58–60], because of multifactorial iron,
folate, or vitamin B12 deficiency, evaluation of hemoglobin
level should be planned, and appropriate replacement
should be evaluated [61].
Consequences of loss of skeletal muscle mass
on chemotherapy tolerance
Loss of muscle mass is a key factor in determining toler-
ance of chemotherapy, as sarcopenia is associated with
increased adverse events [4]. Unfortunately, muscle mass
loss due to treatment-related adverse events or cancer itself
may easily overlap and, the mechanisms by which this
occurs are still unclear.
A first hypothesis to explain the decreased treatment
tolerance is linked to pharmacokinetic distribution of
chemotherapy drugs [4]. Notably, drug doses are usually
administered by calculated body surface area (BSA).
However, patients with similar BSA and BMI may have a
significantly different body composition. Indeed, this cal-
culation method may be potentially misleading because it
does not consider adipose tissue compartment and lean
body mass, mainly represented by skeletal muscle mass
and tissues. Furthermore, many anticancer agents undergo
hepatic and renal metabolism, and BSA is an imperfect
indicator of changes concerning the function of the organs
involved [62].
Since cytotoxic compounds have a narrow therapeutic
index, understanding drug distribution is crucial. Patients
with metabolic disorders usually experience variations in
the distribution, metabolism, and clearance of chemother-
apy agents.
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Obesity may mask a loss of muscle mass, with later
elimination of highly lipophilic drugs in patients with
increased adipose tissue [63]. In these patients, the
administration of chemotherapy doses calculated according
to the BSA can lead to overdosing of antineoplastic drugs
per unit of body weight and to potentially serious side
effects [64]. In addition, not only obese cancer patients
with low muscle mass were reported to have shorter
overall survival compared with patients with healthy
muscle mass but also treatment-induced adverse events
were increased [64].
Many antineoplastic agents are involved in the
development of adverse events in sarcopenic patients
[65–68]. Particularly, it has been demonstrated that
5-fluorouracil increases the risk of loss of skeletal
muscle mass and that patients treated with 5-fluorouracil
who experienced significant adverse events had received
higher doses of the drug when the number of kilograms
of lean body mass was considered [65], suggesting the
need for a dose adjustment according to weight and the
lean body mass [69].
Similarly, in the evaluation of the potential role of S-1 in
the adjuvant setting in GC, it has been demonstrated that
patients with significant loss of muscle had poorer prog-
nosis [70, 71]. Moreover, administration of S-1 for more
than 6 months was identified as an independent risk factor
for reduced muscle mass. Further, drugs that inhibit the
phosphatidylinositol 3-kinase, AKT, and mammalian target
of rapamycin pathway might lead to blockade of cellular
hypertrophy and subsequently loss of muscle mass [68].
Likewise, esophagogastric cancer patients undergoing
neoadjuvant chemotherapy had a shorter overall survival
than patients with healthy muscle mass (569 days vs
1013 days respectively; p = 0.04) [38]. Furthermore,
patients with sarcopenia and chemotherapy-associated
adverse events more often experienced dose reductions of
5-fluorouracil than patients without muscle mass loss.
In a trial evaluating malnutrition in gastrointestinal
cancer, patients were classified according the SGA scale as
well-nourished patients (SGA-A) and malnourished
patients (SGA-B and SGA-C), and it was demonstrated that
the latter had more dose reductions compared with well-
nourished patients. In particular, the proportion of patients
who received chemotherapy in the first 8 weeks of treat-
ment was (88 ± 17)% among well-nourished upper gas-
trointestinal tract cancer patients and (74 ± 25)% among
moderately and severely malnourished upper gastroin-
testinal tract cancer patients (p = 0.01). Furthermore, a
greater proportion of moderately and severely malnour-
ished patients than well-nourished patients discontinued
treatment because of adverse events (18% vs 9%,
p = 0.08), demonstrating a potential impact of sarcopenia
on drug dose density [72].
As pharmacokinetics variability alone does not fully
explain the possible relationship between sarcopenia and
increased frequency of chemotherapy-related adverse
events, other reasons for this association can be comor-
bidities and reduced functional status, which often char-
acterize sarcopenic patients [4]. In addition, the link
between sarcopenia and systemic inflammation may
increase chemotherapy toxicity [44]. Inflammation reduces
cytochrome activities, and impacts on drug metabolism and
elimination, prolonging the exposure to cytotoxic
treatments.
To date, the evidence is insufficient to change clinical
practice, and it is still uncertain how to appropriate modify
drug doses to prevent chemotherapy-related adverse events
in sarcopenic patients.
Hence, further clinical trials should be conducted to
evaluate dose reduction according to the calculation of
muscle mass and muscle density, in order to prevent
adverse events and to ensure greater treatment compliance.
Nutritional support in patients with advanced GC
Even when one is facing patients with inoperable or
metastatic diseases, the early evaluation of their nutritional
status and nutritional support is key to avoid sarcopenia
onset and prevent or delay complications. Malnutrition
occurs in up to 80% of advanced GC patients [44], insuf-
ficient nutrient absorption may cause severe weight loss
[73], and the poor absorption of essential nutrients may
further increase the risk of complications.
Similarly to early stages, in advanced GC patients the
goal of nutritional therapy is to improve the nutritional
status, to increase patients’ adherence to systemic thera-
pies, and to improve their quality of life. Nutritional sup-
port can be provided by oral, enteral, and/or parenteral
nutrition [52]. Intuitively, enteral nutrition is more physi-
ological than parenteral nutrition, preserving the structural
and functional integrity of the gastrointestinal tract, is
safer, is less expensive, and is a valid option for patients
without dysphagia or obstruction [74].
Whenever a mechanical obstruction occurs, the place-
ment of a stent may allow oral physiological nutrition and
improve patients’ quality of life. However, parenteral
nutrition is mandatory in patients with impaired gastroin-
testinal function when inadequate food intake (less than
60% of the estimated energy intake) for more than 10 days
can be expected, as also recommended by the European
Society for Clinical Nutrition and Metabolism guidelines
[75].
Whereas nourishment by central and peripheral veins
ensures optimal nutrition, it increases the risk of infections
when compared with enteral nutrition [76]; catheter-related
Sarcopenia in gastric cancer: when the loss costs too much 567
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bloodstream infections are the commonest and most seri-
ous complications in adult patients receiving parenteral
nutrition [77], although strict adherence to meticulous
insertion and management policies may effectively reduce
catheter-related complications [78]. In terminal-stage dis-
ease the benefit of nutritional support is limited, and may
be associated with an increased risk of complications; in
these cases, nutritional support is recommended only when
benefits prevail over any possible risk [75].
Moreover, home parenteral nutrition is recommended
for weight stabilization and therapy continuation for
patients experiencing chemotherapy-related gastrointesti-
nal adverse events [75, 79]. In addition, home parenteral
nutrition is associated with an improvement in quality of
life, performance status, and nutritional status in advanced
cancer patients with compromised enteral intake and mal-
nutrition, regardless of their tumor type [80]. Thus, total
home parenteral nutrition is mandatory for malnourished
patients with peritoneal carcinomatosis and severe
impairment of gastrointestinal function [81], as well as in
the case of short bowel syndrome due to extensive surgery
[82].
Studies show that the main factors influencing the suc-
cess of parenteral nutrition are patient adherence, adequate
support by a professional and committed nutritionist, and
effective cooperation between the patient, nutritionist,
treating physicians, and home care provider [83].
Target therapies and future perspectives
As sarcopenia and cachexia have an important impact on
GC cancer patients’ prognosis, many novel molecules,
including anabolic agents and anti-inflammatory drugs,
have been developed [84]. An extensive amount of data
support the administration of megestrol acetate and
medroxyprogesterone acetate, with various indications in
cancer patients, including appetite stimulation, weight
gain, and downregulation of proinflammatory cytokines
[85, 86].
To confirm the role in preventing and treating anorex-
ia/cachexia syndrome, the addition of thalidomide to
megestrol acetate therapy was investigated. A significant
increase in body weight (p\ 0.01), quality of life
(p = 0.02), appetite (p = 0.01), and grip strength
(p = 0.01) and a significant decrease in fatigue and Eastern
Cooperative Oncology Group performance status
(p = 0.03) were found in the experimental arm, showing a
higher effectiveness for combination treatment [87]. Fur-
ther combinations of megestrol acetate and other com-
pounds, such as formeterol acetate or mirtazapine, are
being evaluated [88, 89]. Similarly, corticosteroids could
improve appetite, energy, and well-being.
As melatonin was found to be involved in appetite and
nutrient absorption [90], its potential role for appetite
improvement in cachectic cancer patients was investigated
in a double-blind randomized trial. Patients received 20 mg
melatonin per night or matching placebo for 28 days. The
trial was closed early because of futility as no differences
in appetite were reported between the treatment arms in an
interim analysis [91].
After initial enthusiasm [92, 93], enobosarm—a mus-
cular and bone testosterone receptor agonist—failed to
result in an improvement in physical function in advanced
non-small-cell lung cancer patients despite an increase in
lean body mass [94–98].
In addition, anamorelin hydrochloride, an orally active
ghrelin receptor agonist, was tested in two parallel phase
III trials. In both studies, ROMANA 1 [99] and ROMANA
2 [100], 100 mg anamorelin hydrochloride or matching
placebo was given daily at least 1 h before a meal in
addition to platinum and taxanes or platinum and non-
taxane-based chemotherapy for non-small-cell lung cancer
patients. In both trials, patients exposed to anamorelin
hydrochloride had a significantly increased lean body mass
(p\ 0.0001) when compared to those treated with placebo;
moreover, anamorelin hydrochloride was associated with
increased body weight (p\ 0.0001), and improved patient
symptoms (p = 0.0004 and p = 0.0016).
However, both trials failed to show an increase in
handgrip strength, the secondary end point of the two
studies. Thus, considering the so far unmet need of active
drugs for the treatment of cancer-related anorexia/cachexia
syndrome, anamorelin hydrochloride could be considered
as an available option [101]. Complete results of further
trials investigating the effect of this compound on primary
clinical outcomes (e.g., overall survival, disease-free sur-
vival, treatment tolerance) are still awaited [102] (Table 1).
Thus, considering the complex pathogenesis of sar-
copenia, cachexia, and cancer development, clinical treat-
ment of GC patients should include a multimodal approach.
Despite various efforts so far, this multifactorial syndrome
still impacts on patient outcome. Hence, extended results of
ongoing trials, the development of new drugs, and
increased awareness of nutritional support issues among
oncologists are eagerly awaited to better tailor GC patients
treatments [103].
Conclusions
Sarcopenia is a multifactorial clinical condition that leads
to prolonged hospitalization, a higher degree of treatment-
related toxicity and postsurgical complications, reduced
response to cancer treatment, impaired quality of life, and a
worse prognosis in GC patients.
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Early evaluations of nutritional status, including body
composition assessment, and timely nutritional support are
key aspects in the treatment of GC patients with both
operable and advanced disease. A multimodal approach is
necessary to improve clinical outcomes and guarantee an
appropriate support therapy for cancer patients. It should
involve the structured collaboration between oncologists,
surgeons, physiatrists, and clinical nutritionists.
New drugs to counteract lean body mass loss and
enhance the efficacy of nutritional support in cancer
patients are urgently needed. At the same time, clinical
trials should be conducted to calculate the appropriate
chemotherapy dosage according to muscle mass so as to
prevent toxicity and adverse events and to ensure greater
treatment adherence and efficacy.
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